Read the Latest Advances in Pulmonary Hypertension
New Course Release: Screening for Systemic Scleroderma for PAH
New Course Release: Quality of Life and Palliative Care in PAH
PHA's 2014 International PH Conference and Scientific Sessions
2013 Midwest Symposium Presentations
Latest Advances in Pulmonary Hypertension Issue
The Alfred P. Fishman Symposium: New Treatment Approaches to Pulmonary Hypertension, Sonesta Hotel Philadelphia
Philadelphia, PA 19103
Alfred P. Fishman Symposium: New Treatment Approaches to Pulmonary Hypertension, Sonesta Hotel Philadelphia 1800 Market Street Philadelphia, PA 19103
A CME-Certified Event: Saturday, April 26, 2014. In conjunction with: Hospital of the University of Pennsylvania Department of Nursing Education, Innovation and Professional Development.
While lung transplantation was the first therapeutic option available for patients with pulmonary hypertension (and continues to be the ultimate treatment for patients who do not respond to other interventions), the last twenty years have seen a surge in research and development of novel medical therapies.
There are 11 FDA-approved medical therapies for pulmonary arterial hypertension (PAH) and chronic thromboembolic disease. While these treatments have traditionally been classified by the pathophysiologic pathways they target, their clinical effects are complex in terms of patient response, side effects, and dose titration. In addition, new disease pathways have been targeted in recent preclinical and early phase studies, suggesting that more therapies are on the horizon.
PH Treatments: What's on the Horizon,
With the recent FDA approval of three new treatments in just a few months, the past year has brought exciting advances in PH research! Join Dr. Michael McGoon of the Mayo Clinic for a presentation on the current treatments available for PH, as well as new treatments in the pipeline.